Abstract 13445: Precise Score Validation in Buenos Aires 1 Registry

Abstract

Introduction: The PRECICE DAPT Score predicts the bleeding risk in patients treated with dual antiplatelet treatment after primary percutaneous coronary intervention (pPCI). Hypothesis: We sought to assess and compare the prediction power of the PRECISE-DAPT score with regards to bleeding events in patients suffering from non-ST elevation acute coronary syndromes (NSTEACS) and undergoing invasive management in a real- world scenario from Argentina. Methods: Our external validation cohort included 862 patients from Buenos Aires 1 registry. The PRECISE DAPT score was calculated upon admission and the characteristics and evolution of the patients were analyzed in a period of 15 months. The ability of PRECISE-DAPT to predict BARC type 2, 3 or 5 bleeding and BARC type 3 or 5 bleeding and ischemic events (MACE: myocardial infarction, stent thrombosis, or ischemic stroke) during follow up was evaluated. Results: PRECISE-DAPT score was low effective at predicting bleeding events type 2, 3 or 5 (c-statistics 0.58 [95% CI, 0.52-0.61]) moderate at BARC 3 or 5 (c-statistics 0.72 [95% CI, 0.64-0.78]), and poor for MACE (c-statistics 0.49 [95% CI, 0.,45-0.51]). Calibration was accurate (χ2 > 0.05) in all scenarios. High PRECISE-DAPT score (≥25, n= [%]) was associated with very high risk of bleeding (HR 2.1) and ischemic events (HR 1.9) Conclusions: In real-world study, PRECISE DAPT was moderately accurate in predicting bleeding and ischemic events. PRECISE DAPT score ≥25 was able to identify a subgroup of patients with high bleeding and thrombotic events.